Tags

Type your tag names separated by a space and hit enter

A pharmacoeconomic review of the management of respiratory tract infections with moxifloxacin.
Expert Opin Pharmacother. 2008 Jul; 9(10):1735-44.EO

Abstract

BACKGROUND

Moxifloxacin, a fluoroquinolone, has demonstrated its safety and effectiveness in the management of community-acquired pneumonia, acute exacerbations of chronic bronchitis and acute bacterial sinusitis.

OBJECTIVE

The aim of this article was to provide a synthesis and critical appraisal of economic evaluations of the management of respiratory tract infections with moxifloxacin.

METHODS

Studies were included if they assessed the costs and consequences of moxifloxacin as compared with an alternative antimicrobial in the management of community-acquired pneumonia, acute exacerbations of chronic bronchitis or acute bacterial sinusitis.

RESULTS/CONCLUSIONS

Treatment of community-acquired pneumonia, acute exacerbations of chronic bronchitis or acute bacterial sinusitis with moxifloxacin is equally or more effective and less expensive than treatment with other antimicrobials.

Authors+Show Affiliations

Katholieke Universiteit Leuven, Research Centre for Pharmaceutical Care and Pharmaco-economics, Faculty of Pharmaceutical Sciences, Onderwijs en Navorsing 2, Herestraat 49, PO Box 521, 3000 Leuven, Belgium. steven.simoens@pharm.kuleuven.beNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

18570606

Citation

Simoens, Steven, and Marc Decramer. "A Pharmacoeconomic Review of the Management of Respiratory Tract Infections With Moxifloxacin." Expert Opinion On Pharmacotherapy, vol. 9, no. 10, 2008, pp. 1735-44.
Simoens S, Decramer M. A pharmacoeconomic review of the management of respiratory tract infections with moxifloxacin. Expert Opin Pharmacother. 2008;9(10):1735-44.
Simoens, S., & Decramer, M. (2008). A pharmacoeconomic review of the management of respiratory tract infections with moxifloxacin. Expert Opinion On Pharmacotherapy, 9(10), 1735-44. https://doi.org/10.1517/14656566.9.10.1735
Simoens S, Decramer M. A Pharmacoeconomic Review of the Management of Respiratory Tract Infections With Moxifloxacin. Expert Opin Pharmacother. 2008;9(10):1735-44. PubMed PMID: 18570606.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A pharmacoeconomic review of the management of respiratory tract infections with moxifloxacin. AU - Simoens,Steven, AU - Decramer,Marc, PY - 2008/6/24/pubmed PY - 2008/8/12/medline PY - 2008/6/24/entrez SP - 1735 EP - 44 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother VL - 9 IS - 10 N2 - BACKGROUND: Moxifloxacin, a fluoroquinolone, has demonstrated its safety and effectiveness in the management of community-acquired pneumonia, acute exacerbations of chronic bronchitis and acute bacterial sinusitis. OBJECTIVE: The aim of this article was to provide a synthesis and critical appraisal of economic evaluations of the management of respiratory tract infections with moxifloxacin. METHODS: Studies were included if they assessed the costs and consequences of moxifloxacin as compared with an alternative antimicrobial in the management of community-acquired pneumonia, acute exacerbations of chronic bronchitis or acute bacterial sinusitis. RESULTS/CONCLUSIONS: Treatment of community-acquired pneumonia, acute exacerbations of chronic bronchitis or acute bacterial sinusitis with moxifloxacin is equally or more effective and less expensive than treatment with other antimicrobials. SN - 1744-7666 UR - https://www.unboundmedicine.com/medline/citation/18570606/A_pharmacoeconomic_review_of_the_management_of_respiratory_tract_infections_with_moxifloxacin_ L2 - https://www.tandfonline.com/doi/full/10.1517/14656566.9.10.1735 DB - PRIME DP - Unbound Medicine ER -